Predict your next investment

HEALTHCARE | Medical Devices & Equipment / Surgical Devices
pathwaymedical.com

See what CB Insights has to offer

Executives

9

Board of Directors

4

Pathway Medical Technologies Board of Directors

4 Board of directors

Pathway Medical Technologies has 4 board of directors, including Daniel Galles.

Name

Firm

Work History

Other Seats

Daniel Galles

Dan is a partner at Providence Ventures in the San Francisco bay area, where he focuses on investments in the healthcare information technology, healthcare services, and medical device sectors. Dan has been investing in and partnering with management teams of early and growth stage companies in the healthcare industry for over 20 years. Prior to joining Providence, Dan was a Partner at HLM Venture Partners where he led or co-led investments in 14 companies including: Redbrick Health, ClearData, Confluent Surgical, Change Healthcare, and CBR Systems. Prior to HLM, Dan was an Associate at venture capital firm J.H. Whitney and Company and an Analyst in the healthcare investment banking group at Alex. Brown & Sons. Dan has a master’s in business administration from the Kellogg School at Northwestern University and a B.S. in Economics from the Wharton School at the University of Pennsylvania.

Pathway Medical Technologies

J. Daniel Cole

Dan Cole serves as a General Partner of Spray Venture Partners, which he founded in 1996 and a Venture Partner of Oxford Bioscience which he joined in 2009. Dan brings twenty years of medical device operational experience and has served on the Boards of 23 med-tech companies. Prior to joining Spray, Dan served as Senior Vice President and Group President of Boston Scientific Corporation's vascular business, a $1.2 billion group including SCIMED (cardiology), Medi-tech (radiology), Meadox (vascular surgery), and EP Technologies (electrophysiology). He was also responsible for BSC's rapidly growing international operations. Dan was previously President and Chief Operating Officer of SCIMED Life Systems, a public company with revenues of $260 million in 1994 prior to the company's merger with Boston Scientific in 1995. He previously held a variety of executive and general management positions at Baxter Healthcare Divisions. He currently serves on the Board of Directors of superDimension, Pathway Medical, Tryton Medical, Direct Flow Medical, PneumRx, Conventus Orthopedics, and Thoratec Laboratories.

Pathway Medical Technologies

Martien Osch

Martien is a founding partner at Forbion Capital Partners. He splits his time between investment related activities and the finance function. In terms of investment focus, Martien spearheads the medical device related activities at Forbion. He was responsible for the recent exit of Santaris Pharma AS to Roche in August 2014 for up to USD 450 million, the sale of Circulite, Inc. to Heartware, Inc. in December 2013 for up to USD 350 million and of Pathway Medical Technologies, Inc., sold to Bayer Medrad in 2011 for USD 125 million. He currently contributes to the boards of Mitralign, Inc. and PneumRx, Inc. His experience in the life sciences industry also includes prior non-executive board positions at Cambridge Drug Discovery Ltd., Impella Cardiosystems, Acadia Pharmaceuticals and Flowmedica, Inc. Martien holds a degree in Econometrics from the University of Groningen, the Netherlands.

Pathway Medical Technologies

Steve Salmon

Pathway Medical Technologies

Name

Daniel Galles

J. Daniel Cole

Martien Osch

Steve Salmon

Firm

Work History

Dan is a partner at Providence Ventures in the San Francisco bay area, where he focuses on investments in the healthcare information technology, healthcare services, and medical device sectors. Dan has been investing in and partnering with management teams of early and growth stage companies in the healthcare industry for over 20 years. Prior to joining Providence, Dan was a Partner at HLM Venture Partners where he led or co-led investments in 14 companies including: Redbrick Health, ClearData, Confluent Surgical, Change Healthcare, and CBR Systems. Prior to HLM, Dan was an Associate at venture capital firm J.H. Whitney and Company and an Analyst in the healthcare investment banking group at Alex. Brown & Sons. Dan has a master’s in business administration from the Kellogg School at Northwestern University and a B.S. in Economics from the Wharton School at the University of Pennsylvania.

Dan Cole serves as a General Partner of Spray Venture Partners, which he founded in 1996 and a Venture Partner of Oxford Bioscience which he joined in 2009. Dan brings twenty years of medical device operational experience and has served on the Boards of 23 med-tech companies. Prior to joining Spray, Dan served as Senior Vice President and Group President of Boston Scientific Corporation's vascular business, a $1.2 billion group including SCIMED (cardiology), Medi-tech (radiology), Meadox (vascular surgery), and EP Technologies (electrophysiology). He was also responsible for BSC's rapidly growing international operations. Dan was previously President and Chief Operating Officer of SCIMED Life Systems, a public company with revenues of $260 million in 1994 prior to the company's merger with Boston Scientific in 1995. He previously held a variety of executive and general management positions at Baxter Healthcare Divisions. He currently serves on the Board of Directors of superDimension, Pathway Medical, Tryton Medical, Direct Flow Medical, PneumRx, Conventus Orthopedics, and Thoratec Laboratories.

Martien is a founding partner at Forbion Capital Partners. He splits his time between investment related activities and the finance function. In terms of investment focus, Martien spearheads the medical device related activities at Forbion. He was responsible for the recent exit of Santaris Pharma AS to Roche in August 2014 for up to USD 450 million, the sale of Circulite, Inc. to Heartware, Inc. in December 2013 for up to USD 350 million and of Pathway Medical Technologies, Inc., sold to Bayer Medrad in 2011 for USD 125 million. He currently contributes to the boards of Mitralign, Inc. and PneumRx, Inc. His experience in the life sciences industry also includes prior non-executive board positions at Cambridge Drug Discovery Ltd., Impella Cardiosystems, Acadia Pharmaceuticals and Flowmedica, Inc. Martien holds a degree in Econometrics from the University of Groningen, the Netherlands.

Other Seats

Pathway Medical Technologies

Pathway Medical Technologies

Pathway Medical Technologies

Pathway Medical Technologies

Pathway Medical Technologies Management Team

9 Team Members

Pathway Medical Technologies has 9 executives. Pathway Medical Technologies's founder is Thomas Clement. Pathway Medical Technologies's current Chief Executive Officer, President is Paul Buckman.

Name

Work History

Title

Status

Thomas Clement

Founder

Current

Paul Buckman

Chief Executive Officer, President

Current

Michael Behlke

Chief Operating Officer

Current

Edward Wulfman

Chief Technology Officer

Current

Stephanie H Amoss

Senior Vice President

Current

Name

Thomas Clement

Paul Buckman

Michael Behlke

Edward Wulfman

Stephanie H Amoss

Work History

Title

Founder

Chief Executive Officer, President

Chief Operating Officer

Chief Technology Officer

Senior Vice President

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.